Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Johnson

Showing results (201-210 of 244) with videos related to

Pageof 25
Sort By:
Annals of Hematology|February 28, 2021
Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trialJames Russell, Angela Collins, Alexis Fowler, et al.
Blood Advances|January 8, 2025
The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online toolMatthew J Maurer, Susan K Parsons, Jenica N Upshaw, et al.
The New England Journal of Medicine|June 23, 2016
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's LymphomaPeter Johnson, Massimo Federico, Amy Kirkwood, et al.
British Journal of Haematology|May 22, 2020
Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trialMary Gleeson, Nicholas Counsell, David Cunningham, et al.
Haematologica|September 16, 2017
Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trialsDennis A Eichenauer, Ingrid Becker, Ina Monsef, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2013
Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized StudyEmanuele Zucca, Annarita Conconi, Daniele Laszlo, et al.
British Journal of Haematology|May 1, 2018
Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomesSusan K Parsons, Michael J Kelly, Joshua T Cohen, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|March 18, 2022
Development of an Electronic Frailty Index for Hospitalized Older Adults in SwedenJonathan K L Mak, Sara Hägg, Maria Eriksdotter, et al.
British Journal of Cancer|January 4, 2023
The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer careMaria Antonietta Cerone, Tara C Mills, Rowena Sharpe, et al.
Blood|July 1, 2010
Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitutionRonjon Chakraverty, Guillermo Orti, Michael Roughton, et al.
Pageof 25

Showing results (201-210 of 244) with videos related to

Sort By:
Pageof 25
Annals of Hematology|February 28, 2021
Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trialJames Russell, Angela Collins, Alexis Fowler, et al.
Blood Advances|January 8, 2025
The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online toolMatthew J Maurer, Susan K Parsons, Jenica N Upshaw, et al.
The New England Journal of Medicine|June 23, 2016
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's LymphomaPeter Johnson, Massimo Federico, Amy Kirkwood, et al.
British Journal of Haematology|May 22, 2020
Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trialMary Gleeson, Nicholas Counsell, David Cunningham, et al.
Haematologica|September 16, 2017
Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trialsDennis A Eichenauer, Ingrid Becker, Ina Monsef, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2013
Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized StudyEmanuele Zucca, Annarita Conconi, Daniele Laszlo, et al.
British Journal of Haematology|May 1, 2018
Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomesSusan K Parsons, Michael J Kelly, Joshua T Cohen, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|March 18, 2022
Development of an Electronic Frailty Index for Hospitalized Older Adults in SwedenJonathan K L Mak, Sara Hägg, Maria Eriksdotter, et al.
British Journal of Cancer|January 4, 2023
The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer careMaria Antonietta Cerone, Tara C Mills, Rowena Sharpe, et al.
Blood|July 1, 2010
Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitutionRonjon Chakraverty, Guillermo Orti, Michael Roughton, et al.
Pageof 25